-
Product Insights
New![]()
Net Present Value Model: MediWound Ltd’s EscharEx
Determining the value of drugs is a complicated practice and requires a deep knowledge of the drug itself, the current market, and knowledge of expected cash inflows, outflows, and potential success rates for each stage of drug development. GlobalData has done all of this work for you, Drugs Intelligence database to create high-value, risk-adjusted NPV models.
-
Product Insights
New![]()
Net Present Value Model: X4 Pharmaceuticals Inc’s Mavorixafor
Determining the value of drugs is a complicated practice and requires a deep knowledge of the drug itself, the current market, and knowledge of expected cash inflows, outflows, and potential success rates for each stage of drug development. GlobalData has done all of this work for you, Drugs Intelligence database to create high-value, risk-adjusted NPV models.
-
Company Profile
![]()
MediWound Ltd – Company Profile
MediWound Ltd (MediWound) is a biopharmaceutical company that develops, manufactures and markets novel therapeutics to address the unmet needs in the areas of chronic, severe burns, other hard-to-heal wounds and for connective tissue disorders. The company uses its patented proteolytic enzyme technology for the development of its products. The company offers NexoBrid, a drug for the removal of damaged or dead tissue, namely, eschar, in adults with severe burns (deep partial and full-thickness thermal burns). EscharEX, pipeline drug candidate for...
Add to Basket -
Product Insights
New![]()
Likelihood of Approval and Phase Transition Success Rate Model – Prosetin in Amyotrophic Lateral Sclerosis
Overview How likely is it that a drug will get approved? Will the drug transition to the next phase of its clinical pathway? This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. Prosetin in Amyotrophic Lateral Sclerosis Drug Details: Prosetin is under development for the treatment...
-
Product Insights
New![]()
Likelihood of Approval and Phase Transition Success Rate Model – MWPC-005 in Basal Cell Carcinoma (Basal Cell Epithelioma)
Overview How likely is it that a drug will get approved? Will the drug transition to the next phase of its clinical pathway? This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. MWPC-005 in Basal Cell Carcinoma (Basal Cell Epithelioma) Drug Details: MWPC-005 is under development...
-
Product Insights
New![]()
Likelihood of Approval and Phase Transition Success Rate Model – Escharex Second Generation in Venous Leg Ulcers (Crural Ulcer)
OverviewHow likely is it that a drug will get approved? Will the drug transition to the next phase of its clinical pathway? This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData's proprietary machine learning algorithms developed using over 10 years of historical data.Escharex Second Generation in Venous Leg Ulcers (Crural Ulcer)Drug Details:EscharEx second generation (Ex-02) is under development...
-
Product Insights
New![]()
Likelihood of Approval and Phase Transition Success Rate Model – Escharex Second Generation in Diabetic Foot Ulcers
OverviewHow likely is it that a drug will get approved? Will the drug transition to the next phase of its clinical pathway? This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData's proprietary machine learning algorithms developed using over 10 years of historical data.Escharex Second Generation in Diabetic Foot UlcersDrug Details:EscharEx second generation (Ex-02) is under development for the...
-
Product Insights
New![]()
Likelihood of Approval and Phase Transition Success Rate Model – Lanraplenib Succinate in Refractory Acute Myeloid Leukemia
OverviewHow likely is it that a drug will get approved? Will the drug transition to the next phase of its clinical pathway? This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData's proprietary machine learning algorithms developed using over 10 years of historical data.Lanraplenib Succinate in Refractory Acute Myeloid LeukemiaDrug Details:Lanraplenib succinate (GS-9876) is under development for the treatment...
-
Product Insights
New![]()
Likelihood of Approval and Phase Transition Success Rate Model – ABBV-400 in Squamous Non-Small Cell Lung Cancer
Overview How likely is it that a drug will get approved? Will the drug transition to the next phase of its clinical pathway? This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData's proprietary machine learning algorithms developed using over 10 years of historical data. ABBV-400 in Squamous Non-Small Cell Lung Cancer Drug Details: ABBV-400 is under development for...
-
Product Insights
New![]()
Likelihood of Approval and Phase Transition Success Rate Model – Gebasaxturev in Hepatocellular Carcinoma
Overview How likely is it that a drug will get approved? Will the drug transition to the next phase of its clinical pathway? This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData's proprietary machine learning algorithms developed using over 10 years of historical data. Gebasaxturev in Hepatocellular Carcinoma Drug Details: Cavatak (Coxsackievirus A21, CVA-21) is under development for...
-
Product Insights
![]()
Net Present Value Model: EscharEx
Overview Evaluating the value of drugs is a complicated practice and requires a deep knowledge of the drug itself, the market currently and in the future, knowledge of cash inflows and outflows and the potential success rates for each stage of drug development. GlobalData has done all of this work for you, leveraging its gold standard Drugs Intelligence database to create high-value NPV models for purchase on a drug-by-drug basis. Drug Operating Profit Model EscharEx Drug Details EscharEx is under...
-
Product Insights
![]()
Net Present Value Model: NexoBrid
Overview Evaluating the value of drugs is a complicated practice and requires a deep knowledge of the drug itself, the market currently and in the future, knowledge of cash inflows and outflows and the potential success rates for each stage of drug development. GlobalData has done all of this work for you, leveraging its gold standard Drugs Intelligence database to create high-value NPV models for purchase on a drug-by-drug basis. Drug Operating Profit Model NexoBrid Drug Details Bromelains (NexoBrid) is...
-
Product Insights
Wounds Drugs in Development by Stages, Target, MoA, RoA, Molecule Type and Key Players, 2022 Update
A wound is a breakdown in the protective function of the skin (the loss of continuity of epithelium) with or without loss of underlying connective tissue (i.e. muscle, bone, nerves) following injury to the skin or underlying tissues/ organs caused by surgery, a blow, a cut, chemicals, heat/ cold, friction/ shear force, pressure or as a result of diseases, such as leg ulcers or carcinomas. The Wounds pipeline drugs market research report provides comprehensive information on the therapeutics under development...
-
Product Insights
![]()
Likelihood of Approval and Phase Transition Success Rate Model – MWPC-005
Overview How likely is it that a drug will get approved? Will the drug transition to the next phase of its clinical pathway? This report provides you with the data to allow you to track and predict specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using a combination of machine learning and proprietary models. Likelihood of Approval (LoA) - Industry MWPC-005 Drug Details MWPC-005 is under development for the treatment of non-melanoma skin cancer...
-
Product Insights
![]()
Likelihood of Approval and Phase Transition Success Rate Model – EscharEx Second Generation
Overview How likely is it that a drug will get approved? Will the drug transition to the next phase of its clinical pathway? This report provides you with the data to allow you to track and predict specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using a combination of machine learning and proprietary models. Likelihood of Approval (LoA) - Industry EscharEx Second Generation Drug Details EscharEx second generation (Ex-02) is under development for the...
-
Product Insights
![]()
Likelihood of Approval and Phase Transition Success Rate Model – EscharEx
Overview How likely is it that a drug will get approved? Will the drug transition to the next phase of its clinical pathway? This report provides you with the data to allow you to track and predict specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using a combination of machine learning and proprietary models. Likelihood of Approval (LoA) - Industry EscharEx Drug Details EscharEx is under development for the debridement of chronic and other...
-
Product Insights
![]()
Likelihood of Approval and Phase Transition Success Rate Model – bromelains
Overview How likely is it that a drug will get approved? Will the drug transition to the next phase of its clinical pathway? This report provides you with the data to allow you to track and predict specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using a combination of machine learning and proprietary models. Likelihood of Approval (LoA) - Industry bromelains Drug Details Bromelains (NexoBrid) is a protein extract derived from the stems of...
-
Product Insights
Basal Cell Carcinoma (Basal Cell Epithelioma) Drugs in Development by Stages, Target, MoA, RoA, Molecule Type and Key Players, 2022 Update
Basal cell carcinoma is a type of skin cancer which begins in the basal cells. Symptoms include waxy bump, scaly, brown or flesh-colored patch and white, waxy scar. Predisposing factors include age, family history, and exposure to radiation and immunosuppressant medications. The basal cell carcinoma pipeline drugs market research report provides an analysis of the basal cell carcinoma drugs by stage of development, drug target, mechanism of action (MoA), route of administration (RoA), and molecule type. The guide also covers...
-
Product Insights
Actinic (Solar) Keratosis Drugs in Development by Stages, Target, MoA, RoA, Molecule Type and Key Players, 2022 Update
Actinic Keratosis Pipeline Drugs Market Report Overview An actinic keratosis, also known as solar keratosis, is a scaly or crusty growth (lesion). It most often appears on the bald scalp, face, ears, lips, backs of the hands and forearms, shoulders, neck, or any other areas of the body frequently exposed to the sun. The predisposing factors include age, sunny climate, history of frequent or intense sun exposure or sunburn, pale skin, red or blond hair, blue or light-colored eyes, and...
-
Product Insights
Burns Drugs in Development by Stages, Target, MoA, RoA, Molecule Type and Key Players, 2022 Update
A Burn is damage to body's tissues caused by heat, chemicals, electricity, sunlight or radiation. Symptoms include pain, increasing with each degree of burn, red and swollen skin, blisters and charred and blackened skin. Treatment includes antibiotics and pain relievers. The Burn - Drugs in Development research report provides a comprehensive overview on the therapeutics under development for Burn, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The...
Sign up to receive regular alerts for our latest analysis and reports. No matter your industry focus, you can keep your finger on the pulse with our timely updates.